ArticleNature medicine2025
Global lifetime estimates of expected and preventable gastric cancers across 185 countries.
Article in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 62 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparative Analysis of High-Dose Dual Therapies in First-Line Helicobacter Pylori Eradication: A Multicenter Retrospective Study
Efficacy and Safety Assessment of Single-port Robotic Radical Gastrectomy for Gastric Cancer: a Phase 2a Trial Based on the IDEAL Framework
Who cites it
62 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Billroth II With Braun Anastomosis Versus Roux-En-Y Reconstruction Following Distal Gastrectomy: A Systematic Review and Meta-Analysis.World journal of surgery · 2026Pooled it
- Immune checkpoint inhibitors plus trastuzumab and chemotherapy for the treatment of advanced HER2-positive gastric and gastroesophageal junction cancers: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Gastric cancer prevention byFrontiers in oncology · 2026Pooled it
- Global research trends in signaling pathways of spasmolytic polypeptide-expressing metaplasia pathogenesis: a bibliometric analysis.Frontiers in oncology · 2025Pooled it
- Article
- Global burden of cancer attributable to infections in 2024: a worldwide incidence analysis.The Lancet. Oncology · 2026Article
- Lifetime risk of respiratory system cancers across 185 countries: Global variation, socioeconomic inequalities, and ecological associations with air pollution.Preventive medicine reports · 2026Article
- Screening Biomarkers Related to Circadian Rhythm of Gastric Cancer Through Bioinformatics.Applied biochemistry and biotechnology · 2026Article
- Helicobacter pylori eradication treatment dispensing in the Irish General Medical Services population from 2012 to 2022: a repeated cross-sectional analysis.International journal of clinical pharmacy · 2026Article
- Review
- Targeting the DNA-repair chromatin-modifier protein SMYD3 as a novel epigenetics-based therapy for gastric cancer.Journal of experimental & clinical cancer research : CR · 2026Article
- Infection and α-ketoglutarate/oxygen inhibition converge to CDC20 to promote cancer cell aneuploidy.Signal transduction and targeted therapy · 2026Article
- Research Progress and Optimization Strategies of Bispecific Antibody Therapies for CLDN18.2-Positive Gastric Cancer.Journal of gastrointestinal cancer · 2026Review
- Trends inThe Lancet regional health. Western Pacific · 2026Article
- Ubiquitin Specific Peptidase 48 Deubiquitinates METTL3 to Modulate Ferroptosis in Gastric Cancer Cells.Molecular carcinogenesis · 2026Article
- European Cancer Prevention Organization on cancer screening: an expert panel position paper.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026Article
- Alkaloids Mediate Multi-Level Modulation of Gastric Carcinogenesis: From Antibacterial and Anti-Inflammatory Actions to Antitumor Effects.International journal of molecular sciences · 2026Review
- Article
- Article
- From screening to surveillance: integrated prevention ofThe Lancet regional health. Western Pacific · 2026Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Chronic infection with Helicobacter pylori is a modifiable cause of gastric cancer. To assist policymakers in advocating for and planning prevention strategies, we projected the future burden of gastric cancer, including that attributable to H. pylori, among a cohort of young people born in 2008-2017. Expected gastric cancer cases, in the absence of intervention, were quantified in 185 countries by combining national age-specific incidence rates from GLOBOCAN 2022 and cohort-specific mortality rates from the United Nations' demographic projections. Globally, 15.6 million (95% uncertainty interval 14.0-17.3 million) lifetime gastric cancer cases are expected within these birth cohorts, 76% of which are attributable to H. pylori. Two-thirds of cases will be concentrated in Asia, followed by the Americas and Africa. Whereas 58% of cases are expected in traditionally high-incidence areas for gastric cancer, 42% of cases are expected to occur in lower-incidence areas owing to demographic changes, particularly in sub-Saharan Africa, where the future burden could be six times greater than estimated in 2022. A shift in focus toward the life course of today's young people and their prospects of developing gastric cancer, with or without effective interventions, underscores the need for greater investment in gastric cancer prevention, including the implementation of population-based H. pylori screen-and-treat strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.